Carbapenem-resistant hypervirulent Klebsiella pneumoniae infection is associated with significantly higher mortality compared to carbapenem-susceptible strains in 4240 patients.

This systematic review and meta-analysis synthesized data from 79 studies involving a total of 4240 patients to evaluate the clinical burden of hypervirulent Klebsiella pneumoniae (HvKp) infection. The study population comprised patients infected with either carbapenem-susceptible HvKp (CS-HvKp) or carbapenem-resistant HvKp (CR-HvKp). The primary objective was to compare mortality and other clinical outcomes between these two distinct pathogenic profiles. The analysis reveals that the combination of hypervirulence and carbapenem resistance creates a particularly high-risk clinical scenario.

The primary outcome of interest was mortality. The pooled data demonstrated a mortality rate of 21% (95% CI 15-27%) for patients infected with CS-HvKp. In stark contrast, the mortality rate for patients with CR-HvKp infection was 57%. Statistical analysis indicated that the odds of death for patients with CR-HvKp were over 12-fold higher than those with CS-HvKp. This substantial difference underscores the lethal potential of CR-HvKp strains in the current clinical landscape.

Secondary outcomes further characterized the clinical severity of CR-HvKp infection. The rate of liver abscess formation was 24% (95% CI 17-32%) for the overall HvKp population, with the analysis noting that these estimates were influenced by varying diagnostic criteria. Metastatic spread occurred in 22% (95% CI 12-32%) of cases. Additionally, microbiological failure was observed in 39% of patients. These secondary outcomes suggest that CR-HvKp infection is not only more lethal but also more likely to result in complex, disseminated disease and treatment failure.

Safety and tolerability data were not explicitly reported in the provided evidence. Consequently, specific adverse event rates or discontinuation rates due to drug toxicity could not be quantified from this dataset. The study design relies on observational data from multiple sources, which inherently limits the ability to draw definitive causal conclusions regarding specific drug-induced adverse events. The primary driver of poor outcomes identified is the dual mechanism of pathogenicity and resistance rather than specific pharmacological toxicity.

Methodological limitations significantly impact the interpretation of these results. A primary limitation is the lack of a standardized definition for HvKp, which complicates surveillance across the included studies. Outcome estimates vary due to inconsistent definitions of hypervirulence and resistance phenotypes. The influence of diagnostic criteria on the reported rates of liver abscess and metastatic spread was explicitly acknowledged. These inconsistencies introduce potential bias and reduce the precision of the pooled estimates.

The clinical implications of this meta-analysis are profound. Standardized diagnostic criteria and expanded genomic surveillance are essential to improve epidemiological comparability and guide early detection and containment of high-risk HvKp strains. Clinicians must recognize that CR-HvKp represents a distinct and highly dangerous entity compared to CS-HvKp. The impact of these findings on specific treatment protocols is poorly quantified in the current literature, necessitating caution when extrapolating these data to individual patient management decisions.

Several questions remain unanswered regarding the optimal management of CR-HvKp infections. The specific therapeutic strategies that might mitigate the high mortality risk associated with CR-HvKp are not detailed in this analysis. Furthermore, the long-term outcomes and the role of host factors in determining susceptibility to CR-HvKp require further investigation. Until standardized definitions are universally adopted, the true burden of disease and the efficacy of interventions against CR-HvKp will remain difficult to assess accurately.